Baseline and post-treatment circulating tumor cell (CTC) counts with prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy (TRT) in men with metastatic castration-resistant prostate cancer (mCRPC).

作者： David M. Nanus , Scott T. Tagawa , Cora N. Sternberg , Jones T. Nauseef , Joseph Osborne

DOI: 10.1200/JCO.2021.39.6_SUPPL.158

关键词:

摘要: 158Background: CTC counts are an independent prognostic factor in men with mCRPC; certain changes following treatment (conversion from detectable to undetectable or unfavorable favorable) as...

ascopubs.org 本地加速

sci-hub.st HTML 下载加速

参考文章(0)

Baseline and post-treatment circulating tumor cell (CTC) counts with prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy (TRT) in men with metastatic castration-resistant prostate cancer (mCRPC).

来源期刊

我的账户

Baseline and post-treatment circulating tumor cell (CTC) counts with prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy (TRT) in men with metastatic castration-resistant prostate cancer (mCRPC).

来源期刊

相似文章 0

我的账户